Ahmad Zain
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Ahmad Zain has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Aamna Dilshad
Department of Biological Sciences, International Islamic University, Islamabad, Pakistan
1 shared publication - Akhil Raj Anumolu
Andhra Medical College
1 shared publication Al Haisbuzzaman
Department of Medicine, Niramoy Hospital, Panchagarh, Bangladesh
1 shared publication- Alina Sehar
Internal Medicine, United Medical and Dental College, Karachi, PAK
1 shared publication - Alishba Mbbs Jawaid
Department of Medicine, Karachi Medical and Dental College, Karachi, Pakistan
1 shared publication - Allahdad Khan
Department of Medicine, Nishtar Medical University, Multan, Pakistan
1 shared publication
Latest Publications
- Open Access
- 28 May 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (6)
Silent Megacolon: Fulminant Clostridioides Difficile Infection Without Diarrhea Mimicking Acute Colonic Pseudo-Obstruction
Clostridioides difficile infection (CDI) typically presents with diarrhea in elderly or antibiotic-exposed patients. We report a 40-year-old immunocompetent man with alcohol use disorder who presented with abdominal pain and jaundice, rapidly progressing to refractory constipation and colonic dilation (14.7 cm) mimicking acute colonic pseudo-obstruction. Conservative management including bowel regimens and neostigmine (generally contraindicated in suspected toxic megacolon) were attempted. Colonoscopic decompression revealed cecal pseudomembranes whereas rest of colon was grossly normal. Stool testing showed discordant results that is, negative toxin enzyme immunoassay but positive stool polymerase chain reaction (Nucleic Acid Amplification Testing), supporting CDI in appropriate clinical context. Despite appropriate broad-spectrum antibiotics and emergent subtotal colectomy for fulminant disease with ischemic changes, he developed septic shock and multiorgan failure. This atypical, fulminant CDI presentation without diarrhea, initially mimicking acute colonic pseudo-obstruction, with isolated cecum and ileum involvement, underscores diagnostic pitfalls and need for early polymerase chain reaction/endoscopy in unexplained megacolon.
- 28 May 2026
- Published by Wolters Kluwer Health in ACG Case Reports Journal
- Vol. 13 (6)
Open AccessSilent Megacolon: Fulminant Clostridioides Difficile Infection Without Diarrhea Mimicking Acute Colonic Pseudo-Obstruction
Clostridioides difficile infection (CDI) typically presents with diarrhea in elderly or antibiotic-exposed patients. We report a 40-year-old immunocompetent man with alcohol use disorder who presented with abdominal pain and jaundice, rapidly progressing to refractory constipation and colonic dilation (14.7 cm) mimicking acute colonic pseudo-obstruction. Conservative management including bowel regimens and neostigmine (generally contraindicated in suspected toxic megacolon) were attempted. Colonoscopic decompression revealed cecal pseudomembranes whereas rest of colon was grossly normal. Stool testing showed discordant results that is, negative toxin enzyme immunoassay but positive stool polymerase chain reaction (Nucleic Acid Amplification Testing), supporting CDI in appropriate clinical context. Despite appropriate broad-spectrum antibiotics and emergent subtotal colectomy for fulminant disease with ischemic changes, he developed septic shock and multiorgan failure. This atypical, fulminant CDI presentation without diarrhea, initially mimicking acute colonic pseudo-obstruction, with isolated cecum and ileum involvement, underscores diagnostic pitfalls and need for early polymerase chain reaction/endoscopy in unexplained megacolon.
- Open Access
- 29 September 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science – Atherosclerotic Diseases
- Vol. 10 (1) , 211-219
Trends in mortality from acute myocardial infarction among the obese population in the United States from 1999 to 2020: insights from CDC WONDER
Introduction: Acute myocardial infarction (AMI) remains a leading cause of death globally, with obesity identified as a significant risk factor for increased incidence and poorer post-event outcomes. Understanding trends in AMI mortality among obese populations is crucial for informing public health strategies, especially in light of rising obesity rates.Material and methods: This retrospective study analyzed data from the CDC WONDER database to examine AMI-related mortality among obese individuals (ICD-10 codes I21 for AMI and E66 for obesity) from 1999 to 2020. Mortality rates were assessed using crude mortality rates (CMR) and age-adjusted mortality rates (AAMR) per 100,000, stratified by year, gender, race/ethnicity, state, and urban-rural status. Average annual percent change (AAPC) was calculated to identify trends over the study period.Results: From 1999 to 2020, there were 39,793 obesity-related AMI deaths. The AAPC for the entire period was 1.75 (95% CI: 1.06 to 2.45, p < 0.001). For men, the AAPC was 2.81, while for women, it was 1.12. Notably, African American individuals saw a significant increase in AMI mortality from 2018 to 2020 (AAPC = 19.28). Geographically, the Midwest, South, and West regions experienced upward trends, while the Northeast saw a slight decline. Smaller metropolitan and non-metropolitan areas showed consistent increases.Conclusions: The study highlights an upward trend in AMI-related mortality among the obese population in the U.S. from 1999 to 2020. Targeted public health interventions are needed to address these trends, particularly in high-risk populations.
- 29 September 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science – Atherosclerotic Diseases
- Vol. 10 (1) , 211-219
Open AccessTrends in mortality from acute myocardial infarction among the obese population in the United States from 1999 to 2020: insights from CDC WONDER
Introduction: Acute myocardial infarction (AMI) remains a leading cause of death globally, with obesity identified as a significant risk factor for increased incidence and poorer post-event outcomes. Understanding trends in AMI mortality among obese populations is crucial for informing public health strategies, especially in light of rising obesity rates.Material and methods: This retrospective study analyzed data from the CDC WONDER database to examine AMI-related mortality among obese individuals (ICD-10 codes I21 for AMI and E66 for obesity) from 1999 to 2020. Mortality rates were assessed using crude mortality rates (CMR) and age-adjusted mortality rates (AAMR) per 100,000, stratified by year, gender, race/ethnicity, state, and urban-rural status. Average annual percent change (AAPC) was calculated to identify trends over the study period.Results: From 1999 to 2020, there were 39,793 obesity-related AMI deaths. The AAPC for the entire period was 1.75 (95% CI: 1.06 to 2.45, p < 0.001). For men, the AAPC was 2.81, while for women, it was 1.12. Notably, African American individuals saw a significant increase in AMI mortality from 2018 to 2020 (AAPC = 19.28). Geographically, the Midwest, South, and West regions experienced upward trends, while the Northeast saw a slight decline. Smaller metropolitan and non-metropolitan areas showed consistent increases.Conclusions: The study highlights an upward trend in AMI-related mortality among the obese population in the U.S. from 1999 to 2020. Targeted public health interventions are needed to address these trends, particularly in high-risk populations.
- Open Access
- 16 October 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (12) , 7072-7081
Efficacy and safety of the FGF19 analog aldafermin for the treatment of nonalcoholic steatohepatitis: a GRADE assessed systematic review and meta-analysis
Background: Nonalcoholic fatty liver disease (NAFLD) is increasingly concerning due to its rising prevalence. It encompasses conditions from simple steatosis to severe nonalcoholic steatohepatitis (NASH), posing risks such as fibrosis, cirrhosis, or hepatocellular carcinoma if untreated. This systematic review and meta-analysis aims to assess aldafermin, an FGF19 analog, for efficacy and safety in NASH patients. Methods: Eligible studies were identified by searching PubMed, Cochrane Library, and Google Scholar, resulting in 1115 studies. Three RCTs were included. The risk of bias was assessed using the Cochrane Risk of Bias tool, and data synthesis utilized Review Manager software. The certainty of evidence was evaluated with the GRADE approach. Results: In the 3 mg dose group, aldafermin significantly improved various parameters. The ELF score decreased notably (pooled MD: −0.46, 95% CI: −0.64 to −0.28; P P P =0.02). Furthermore, significant reductions were noted in absolute AST levels (pooled MD: −13.40, 95% CI: −18.66 to −8.14; P P <0.00001), suggesting improved liver function. Conclusion: The meta-analysis indicates that aldafermin, particularly, the 3 mg dose, shows significant efficacy in improving liver histology and biochemical markers in NASH patients compared to placebo, along with a satisfactory safety profile.
- 16 October 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (12) , 7072-7081
Open AccessEfficacy and safety of the FGF19 analog aldafermin for the treatment of nonalcoholic steatohepatitis: a GRADE assessed systematic review and meta-analysis
Background: Nonalcoholic fatty liver disease (NAFLD) is increasingly concerning due to its rising prevalence. It encompasses conditions from simple steatosis to severe nonalcoholic steatohepatitis (NASH), posing risks such as fibrosis, cirrhosis, or hepatocellular carcinoma if untreated. This systematic review and meta-analysis aims to assess aldafermin, an FGF19 analog, for efficacy and safety in NASH patients. Methods: Eligible studies were identified by searching PubMed, Cochrane Library, and Google Scholar, resulting in 1115 studies. Three RCTs were included. The risk of bias was assessed using the Cochrane Risk of Bias tool, and data synthesis utilized Review Manager software. The certainty of evidence was evaluated with the GRADE approach. Results: In the 3 mg dose group, aldafermin significantly improved various parameters. The ELF score decreased notably (pooled MD: −0.46, 95% CI: −0.64 to −0.28; P P P =0.02). Furthermore, significant reductions were noted in absolute AST levels (pooled MD: −13.40, 95% CI: −18.66 to −8.14; P P <0.00001), suggesting improved liver function. Conclusion: The meta-analysis indicates that aldafermin, particularly, the 3 mg dose, shows significant efficacy in improving liver histology and biochemical markers in NASH patients compared to placebo, along with a satisfactory safety profile.
- Open Access
- 14 August 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (10) , 5938-5946
CRISPR/Cas9 in the treatment of sickle cell disease (SCD) and its comparison with traditional treatment approaches: a review
Sickle cell disease (SCD) is a common hereditary blood disorder that profoundly impacts individuals’ health, causing chronic pain, anemia, organ damage, increased susceptibility to infections, and social and psychological effects. Over the years, advances in treatment have improved the long-term outcomes of SCD patients. However, problems such as limited access to hematopoietic stem cell transplantation (HSCT) and potential complications associated with the available therapies underscore the importance of continued research and development. The recent FDA approval of Casgevy (Exagamglogene autotemcel), a genetic therapy based on CRISPR/Cas9 technology, demonstrates a comprehensive effort to address the complexity of SCD using new technologies. This review explores the potential of CRISPR/Cas9 for treating SCD and evaluates its efficacy, safety, and long-term outcomes compared to traditional treatment approaches. Long-term research is needed to comprehensively assess the safety, effectiveness, and inclusion of CRISPR/Cas9, ensuring its overall efficacy.
- 14 August 2024
- Published by Wolters Kluwer Health in Annals of Medicine & Surgery
- Vol. 86 (10) , 5938-5946
Open AccessCRISPR/Cas9 in the treatment of sickle cell disease (SCD) and its comparison with traditional treatment approaches: a review
Sickle cell disease (SCD) is a common hereditary blood disorder that profoundly impacts individuals’ health, causing chronic pain, anemia, organ damage, increased susceptibility to infections, and social and psychological effects. Over the years, advances in treatment have improved the long-term outcomes of SCD patients. However, problems such as limited access to hematopoietic stem cell transplantation (HSCT) and potential complications associated with the available therapies underscore the importance of continued research and development. The recent FDA approval of Casgevy (Exagamglogene autotemcel), a genetic therapy based on CRISPR/Cas9 technology, demonstrates a comprehensive effort to address the complexity of SCD using new technologies. This review explores the potential of CRISPR/Cas9 for treating SCD and evaluates its efficacy, safety, and long-term outcomes compared to traditional treatment approaches. Long-term research is needed to comprehensively assess the safety, effectiveness, and inclusion of CRISPR/Cas9, ensuring its overall efficacy.
- 1 August 2022
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 16 (8) , 102588
Effects of testosterone therapy in adult males with hypogonadism and T2DM: A meta-analysis and systematic review
- 1 August 2022
- Published by Elsevier in Diabetes & Metabolic Syndrome: Clinical Research & Reviews
- Vol. 16 (8) , 102588
Effects of testosterone therapy in adult males with hypogonadism and T2DM: A meta-analysis and systematic review